• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

用于治疗膀胱过度活动症的米拉贝隆对女性性功能的影响：一项前瞻性对照研究。

The effect of mirabegron, used for overactive bladder treatment, on female sexual function: a prospective controlled study.

作者信息

Zachariou A, Mamoulakis C, Filiponi M, Dimitriadis F, Giannakis J, Skouros S, Tsounapi P, Takenaka A, Sofikitis N

机构信息

Department of Urology, School of Medicine, Ioannina University, Ioannina, Greece.

, 3 Spyridi Street, 38221, Volos, Greece.

出版信息

BMC Urol. 2018 Jun 25;18(1):61. doi: 10.1186/s12894-018-0377-9.

DOI:10.1186/s12894-018-0377-9
PMID:29940933
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6020185/
Abstract

BACKGROUND

Αim of the study was to determine the effect of mirabegron, used for overactive bladder (OAB) treatment, on female sexual function.

METHODS

Eighty five sexually active women suffering from overactive bladder were prospectively enrolled in this study. Females were divided into two groups. In Group A (control), 48 patients received no treatment and in Group B, 37 patients received mirabegron 50 mg/daily for 3 months. Patients were evaluated with FSFI-Gr at the beginning of the study and again after a period of 3 months.

RESULTS

In Group B, there was a significant increase post-treatment compared to baseline (p < 0.001) in total FSFI (20.3 (3.8) to 26.6 (4.2)) and all domains (desire: 3.0 (1.2) to 4.8 (1.2)), arousal: 3.0 (0.8) to 4.8 (0.9), lubrication: 3.9 (1.1) to 4.8 (1.2), orgasm: 3.6 (0.8) to 4.8 (1.0), satisfaction: 3.2 (0.4) to 4.0 (0.8) and pain: 3.2 (0.8) to 4.4 (1.2)). In Group A, there were no statistically significant changes in pre- and post-observation values.

CONCLUSIONS

This study is one of the few demonstrating that management of OAB with mirabegron improves female sexual function.

TRIAL REGISTRATION

TRN ISRCTN17199301 , 20/10/2017, retrospectively registered.

摘要

背景

本研究旨在确定用于治疗膀胱过度活动症（OAB）的米拉贝隆对女性性功能的影响。

方法

前瞻性纳入85名患有膀胱过度活动症的性活跃女性。将女性分为两组。A组（对照组）48例患者未接受治疗，B组37例患者接受米拉贝隆50毫克/天治疗，为期3个月。在研究开始时和3个月后，使用FSFI-Gr对患者进行评估。

结果

B组治疗后总FSFI（从20.3（3.8）增至26.6（4.2））及所有领域（性欲：从3.0（1.2）增至4.8（1.2））、性唤起：从3.0（0.8）增至4.8（0.9）、润滑：从3.9（1.1）增至4.8（1.2）、性高潮：从3.6（0.8）增至4.8（1.0）、满意度：从3.2（0.4）增至4.0（0.8）、疼痛：从3.2（0.8）增至4.4（1.2））与基线相比均有显著增加（p < 0.001）。A组观察前后的值无统计学显著变化。

结论

本研究是少数表明使用米拉贝隆治疗膀胱过度活动症可改善女性性功能的研究之一。

试验注册

TRN ISRCTN17199301，2017年10月20日，回顾性注册。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/296d/6020185/7aef6bdad2f6/12894_2018_377_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/296d/6020185/7aef6bdad2f6/12894_2018_377_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/296d/6020185/7aef6bdad2f6/12894_2018_377_Fig1_HTML.jpg

相似文献

1
The effect of mirabegron, used for overactive bladder treatment, on female sexual function: a prospective controlled study.用于治疗膀胱过度活动症的米拉贝隆对女性性功能的影响：一项前瞻性对照研究。
BMC Urol. 2018 Jun 25;18(1):61. doi: 10.1186/s12894-018-0377-9.
2
The impact of Mirabegron on sexual function in women with idiopathic overactive bladder.米拉贝隆对特发性膀胱过度活动症女性性功能的影响。
BMC Urol. 2019 Jan 21;19(1):7. doi: 10.1186/s12894-019-0438-8.
3
Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony).米拉贝隆与索利那新联合治疗膀胱过度活动症患者的疗效和安全性：一项随机、双盲、剂量范围、2 期研究（Symphony）的结果。
Eur Urol. 2015 Mar;67(3):577-88. doi: 10.1016/j.eururo.2014.02.012. Epub 2014 Feb 19.
4
Efficacy of transcutaneous electrical nerve stimulation combined with mirabegron therapy compared with mirabegron monotherapy for overactive bladder: a prospective randomized controlled study.经皮神经电刺激联合米拉贝隆治疗与米拉贝隆单药治疗对膀胱过度活动症的疗效比较：一项前瞻性随机对照研究。
World J Urol. 2024 Jun 7;42(1):370. doi: 10.1007/s00345-024-05084-0.
5
Mirabegron for overactive bladder in frail patients 80 years or over (HOKUTO study).米拉贝隆治疗 80 岁及以上虚弱患者的膀胱过度活动症（HOKUTO 研究）。
BMC Urol. 2022 Mar 21;22(1):40. doi: 10.1186/s12894-022-00989-7.
6
Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a β3-adrenoceptor agonist, in patients with overactive bladder in Asia.β3肾上腺素能受体激动剂米拉贝隆在亚洲膀胱过度活动症患者中进行的一项随机、双盲、平行组、安慰剂和活性药物对照的多中心研究结果。
Neurourol Urodyn. 2015 Sep;34(7):685-92. doi: 10.1002/nau.22645. Epub 2014 Aug 17.
7
Mirabegron versus Solifenacin in Children with Overactive Bladder: Prospective Randomized Single-Blind Controlled Trial.米拉贝隆与索利那新治疗儿童膀胱过度活动症的前瞻性随机单盲对照试验
Urol Int. 2021;105(11-12):1011-1017. doi: 10.1159/000515992. Epub 2021 May 19.
8
Efficacy and Safety of Mirabegron in Men with Overactive Bladder Symptoms and Benign Prostatic Hyperplasia.米拉贝隆治疗膀胱过度活动症合并良性前列腺增生症患者的疗效和安全性。
Curr Urol Rep. 2021 Jan 7;22(1):5. doi: 10.1007/s11934-020-01017-7.
9
Comparative Efficacy and Tolerability of Antimuscarinic Agents and the Selective β3-Adrenoceptor Agonist, Mirabegron, for the Treatment of Overactive Bladder: Which is More Preferable as an Initial Treatment?抗毒蕈碱药物与选择性β3肾上腺素能受体激动剂米拉贝隆治疗膀胱过度活动症的疗效和耐受性比较：哪种作为初始治疗更可取？
Low Urin Tract Symptoms. 2018 May;10(2):158-166. doi: 10.1111/luts.12153. Epub 2016 Dec 23.
10
Critical analysis of phase II and III randomised control trials (RCTs) evaluating efficacy and tolerability of a β₃-adrenoceptor agonist (Mirabegron) for overactive bladder (OAB).评价 β₃-肾上腺素能受体激动剂（米拉贝隆）治疗膀胱过度活动症（OAB）的疗效和耐受性的 II 期和 III 期随机对照试验（RCT）的批判性分析。
BJU Int. 2015 Jan;115(1):32-40. doi: 10.1111/bju.12730. Epub 2014 Jul 27.

引用本文的文献

1
A comparative study of mirabegron versus doxazosin in improving ureteral stent-related dysfunction.米拉贝隆与多沙唑嗪改善输尿管支架相关功能障碍的比较研究。
World J Urol. 2025 May 13;43(1):299. doi: 10.1007/s00345-025-05663-9.
2
The impact of pharmacotherapy on sexual function in female patients being treated for idiopathic overactive bladder: a systematic review.药物治疗对特发性膀胱过度活动症女性患者性功能的影响：系统评价。
BMC Womens Health. 2024 May 16;24(1):290. doi: 10.1186/s12905-024-03103-1.
3
STOMp: sexual function trial of overactive bladder medication.

本文引用的文献

1
Translation and validation of the Greek version of the female sexual function index questionnaire.女性性功能指数问卷希腊语版本的翻译与验证
Int J Impot Res. 2017 Jul;29(4):171-174. doi: 10.1038/ijir.2017.18. Epub 2017 Apr 20.
2
Diagnosing Sexual Dysfunction in Men and Women: Sexual History Taking and the Role of Symptom Scales and Questionnaires.男性和女性性功能障碍的诊断：性史采集以及症状量表和问卷的作用。
J Sex Med. 2016 Aug;13(8):1166-82. doi: 10.1016/j.jsxm.2016.05.017.
3
Mirabegron causes relaxation of human and rat corpus cavernosum: could it be a potential therapy for erectile dysfunction?
STOMp：膀胱过度活动症药物性功能试验
Sex Med. 2023 Jan 12;11(1):qfac001. doi: 10.1093/sexmed/qfac001. eCollection 2023 Feb.
4
Quality of Life, Psychological Wellbeing, and Sexuality in Women with Urinary Incontinence-Where Are We Now: A Narrative Review.女性尿失禁患者的生活质量、心理幸福感和性生活：我们现在在哪里：一篇叙述性综述。
Medicina (Kaunas). 2022 Apr 9;58(4):525. doi: 10.3390/medicina58040525.
5
Impact of intravesical onabotulinumtoxinA (Botox) on sexual function in patients with overactive bladder syndrome: a systematic review and meta-analysis.膀胱内注射A型肉毒杆菌毒素（保妥适）对膀胱过度活动症患者性功能的影响：一项系统评价和荟萃分析。
Int Urogynecol J. 2022 Feb;33(2):235-243. doi: 10.1007/s00192-021-05072-7. Epub 2022 Jan 13.
6
Overactive Bladder Syndrome Treatments and Their Effect on Female Sexual Function: A Review.膀胱过度活动症的治疗及其对女性性功能的影响：综述
Sex Med. 2020 Mar;8(1):1-7. doi: 10.1016/j.esxm.2019.08.013. Epub 2019 Oct 9.
7
The effect of overactive bladder treatment with anticholinergics on female sexual function in women: a prospective observational study.抗胆碱能药物治疗膀胱过度活动症对女性性功能的影响：一项前瞻性观察研究。
Int Urol Nephrol. 2019 Jan;51(1):27-32. doi: 10.1007/s11255-018-2030-7. Epub 2018 Nov 17.
米拉贝隆可使人体和大鼠阴茎海绵体舒张：它能否成为治疗勃起功能障碍的潜在疗法？
BJU Int. 2016 Sep;118(3):464-74. doi: 10.1111/bju.13515. Epub 2016 May 26.
4
Impact of treatment of overactive bladder with anticholinergics on sexual function.抗胆碱能药物治疗膀胱过度活动症对性功能的影响。
Arch Gynecol Obstet. 2016 Feb;293(2):403-6. doi: 10.1007/s00404-015-3828-5. Epub 2015 Jul 30.
5
Phase III, randomised, double-blind, placebo-controlled study of the β3-adrenoceptor agonist mirabegron, 50 mg once daily, in Japanese patients with overactive bladder.III 期、随机、双盲、安慰剂对照研究β3-肾上腺素能受体激动剂米拉贝隆，每日 50mg，治疗日本膀胱过度活动症患者。
BJU Int. 2014 Jun;113(6):951-60. doi: 10.1111/bju.12649. Epub 2014 Mar 17.
6
A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the β₃ adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder.一项评估β₃肾上腺素能受体激动剂米拉贝隆治疗膀胱过度活动症患者症状的疗效和安全性的 III 期、随机、双盲、平行分组、安慰剂对照、多中心研究。
Urology. 2013 Aug;82(2):313-20. doi: 10.1016/j.urology.2013.02.077. Epub 2013 Jun 13.
7
Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies.米拉贝隆治疗膀胱过度活动症：三项随机、双盲、安慰剂对照、III 期研究的预先设定的汇总疗效分析和汇总安全性分析。
Int J Clin Pract. 2013 Jul;67(7):619-32. doi: 10.1111/ijcp.12194. Epub 2013 May 21.
8
Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladder.米拉贝隆治疗膀胱过度活动症的随机、双盲、阳性药物对照 3 期临床试验：12 个月安全性和疗效评估
Eur Urol. 2013 Feb;63(2):296-305. doi: 10.1016/j.eururo.2012.10.048. Epub 2012 Nov 6.
9
Efficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial.米拉贝隆（一种β（3）-肾上腺素能受体激动剂）治疗膀胱过度活动症的疗效和耐受性：一项随机、欧洲-澳大利亚 3 期试验的结果。
Eur Urol. 2013 Feb;63(2):283-95. doi: 10.1016/j.eururo.2012.10.016. Epub 2012 Nov 6.
10
Results of a randomized phase III trial of mirabegron in patients with overactive bladder.米拉贝隆治疗膀胱过度活动症的随机 III 期临床试验结果。
J Urol. 2013 Apr;189(4):1388-95. doi: 10.1016/j.juro.2012.10.017. Epub 2012 Oct 16.